Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02359851
Title Pembrolizumab in Treating Patients With Advanced Uveal Melanoma
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Vanderbilt-Ingram Cancer Center
Indications

uveal melanoma

Therapies

Pembrolizumab

Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
University of Chicago Chicago Illinois 60637 United States Details
Vanderbilt-Ingram Cancer Center Nashville Tennessee 37232 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field